Extended Data Fig. 9: Matched whole genome sequencing data validates fCpGs as a phylogenetic character.
From: Fluctuating DNA methylation tracks cancer evolution at clinical scale
a-b: Corresponding phylogenies reconstructed on matched WGS SNVs for CLL case 12 and 19 to Fig. 4a,b, respectively. c-e: The reconstructed phylogenies of the relationship between samples collected longitudinally in 3 individual ALL patients, annotated with the clinical classification of each sample. The black triangles represent the time that occurred since the most recent common ancestor, taken as the posterior median of T - τ from the single-sample EVOFLUx inferences. f: Paired boxplot showing the standard deviation of the fCpG methylation distributions of B-ALL samples is greater than their matched remission sample (p = 9.6e-39, paired t-test). g: Comparison of the standard deviation of the fCpG methylation distributions of B-ALL patients in remission (i.e. no cancer cells present in blood) vs normal whole blood (p = 0.067, MW-U test). h: Example longitudinal samples from one patient showing the development of the fCpG distribution from diagnostic B-ALL, through remission and relapse. i: Scatterplots showing the marginal fCpG methylation distribution between diagnosis and relapse for the ALL case in h.
